{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-002146","form_type":"8-K","ticker":"PROF","cik":"0001628808","company_name":"Profound Medical Corp.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.616086+00:00","generated_at":"2026-05-15T07:58:54.074400+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Profound Medical to present TULSA-PRO data at SIR 2026 in Toronto, April 11-15","bullets":["Five oral presentations on April 12 during 'Men's Health 1' session at SIR Annual Meeting.","Categorical course 'Prostate Interventions: TULSA and Beyond' on April 13 featuring TULSA.","Presentations include CAPTAIN trial data comparing TULSA vs robotic prostatectomy for intermediate-risk prostate cancer.","Other topics: TULSA for recurrent prostate cancer, extreme apex cancer, and automated segmentation validation.","CEO says growing acceptance of TULSA as mainstream treatment for prostate disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002146","json":"https://secwatch.observer/filing/0001171843-26-002146.json","markdown":"https://secwatch.observer/filing/0001171843-26-002146.md","text":"https://secwatch.observer/filing/0001171843-26-002146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326002146/0001171843-26-002146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326002146/f8k_040126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:58:54.074400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}